Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To assess the clinical and cost-effectiveness of zaleplon, zolpidem and zopiclone (Z-drugs) compared with benzodiazepines. DATA SOURCES: Electronic databases, reference lists of retrieved articles and pharmaceutical company submissions. REVIEW METHODS: Randomised controlled trials (RCTs) that compared either benzodiazepines to the Z-drugs or any two of the non-benzodiazepine drugs in patients with insomnia were included in the review. Data on the following outcome measures were considered: sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse effects and rebound insomnia. A search was also undertaken for any study designs that evaluated issues related to adverse events (e.g. dependency and withdrawal symptoms). Full economic evaluations that compared two or more options and considered both costs and consequences including cost-effectiveness, cost-utility analysis or cost-benefit analysis undertaken in the context of high-quality RCTs were considered for inclusion in the review. RESULTS: Twenty-four studies, involving a total study population of 3909 patients, met the inclusion criteria. These included 17 studies comparing a Z-drug with a benzodiazepine and seven comparing a Z-drug with another Z-drug. The diversity of possible comparisons and the range of outcome measures in the review may be confusing. Outcomes were rarely standardised and, even when reported, differed in interpretation. In addition, variations in assessment and variety in the level of information provided make study comparisons difficult. As a result, meta-analysis has been possible on only a small number of outcomes. However, some broad conclusions might be reached based on the limited data provided. The existing published economic literature in this area is very limited. No relevant economic evaluations were identified for inclusion in the review. The industry submissions did not include detailed evidence of cost-effectiveness. Given the lack of robust clinical evidence, no economic model describing the costs and benefits of the newer hypnotic drugs for insomnia was developed. The systematic review provided in this report suggests that an agnostic approach to cost-effectiveness is required at this stage. In the short-term, no systematic evidence is available concerning significant outcome variations between either the different classes of drugs or between individual drugs within each class. Within this short-term horizon, the one element that does vary significantly is the acquisition cost of the individual drugs. CONCLUSIONS: The short-acting drugs seem equally effective and safe with minor differences that may lead a prescriber to favour one over another in different patients. There is no evidence that one is more cost-effective than any other. Analysis of the additional costs to the NHS, depending on the rate of change from benzodiazepine prescriptions to Z-drug prescriptions, at current levels of hypnotic prescribing, range from GBP2 million to GBP17 million per year. There are clear research needs in this area; in particular, none of the existing trials adequately compare these medications. It is suggested that further consideration should be given to a formal trial to allow head-to-head comparison of some of the key drugs in a double-blind RCT lasting at least 2 weeks, and of sufficient size to draw reasonable conclusions. We would also recommend that any such trial should include a placebo arm. It should also collect good-quality data around sleep outcomes and in particular quality of life and daytime drowsiness. We do not believe that any formal study of risk of dependency is feasible at present. Finally, the management of long-term insomnia is suggested for further investigation: considering the frequency of this symptom and its recurring course, the short-term trial of medication and lack of long-term follow-up undermine attempts to develop evidence-based guidelines for the use of hypnotics in this condition, or indeed for its whole management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Epidemiology of insomnia: what we know and what we still need to learn
Ohayon, M. M. (2002) · Sleep Medicine Reviews · doi:10.1053/smrv.2002.0186 · Cited by 3,743
Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1172 · Cited by 1,098
Comparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863
Prevalence, burden, and treatment of insomnia in primary care
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.10.1417 · Cited by 694
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Evaluation of Chronic Insomnia
Sateia, M. J., Doghramji, K., Hauri, P. J., & Morin, C. M. (2000) · Sleep · doi:10.1093/sleep/23.2.1l · Cited by 466
Epidemiological Study on Insomnia in the General Population
Ohayon, M. (1996) · Sleep · doi:10.1093/sleep/19.suppl_3.s7 · Cited by 401
SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers
Léger, D., Scheuermaier, K., Philip, P., Paillard, M., & Guilleminault, C. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200101000-00006 · Cited by 377
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
Riemann, D., & Perlis, M. L. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.06.001 · Cited by 477
Valerian for Sleep: A Systematic Review and Meta-Analysis
Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.026 · Cited by 387
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Huedo-Medina, T. B., Kirsch, I., Middlemass, J., Klonizakis, M., & Siriwardena, A. N. (2012) · BMJ · doi:10.1136/bmj.e8343 · Cited by 313
Sleep/Wake Disturbances in People With Cancer and Their Caregivers: State of the Science
Berger, A. M., Parker, K. P., Young-McCaughan, S., Mallory, G. A., Barsevick, A. M., Beck, S. L., Carpenter, J. S., Carter, P. A., Farr, L. A., Hinds, P. S., et al. (2005) · Oncology Nursing Forum · doi:10.1188/05.onf.e98-e126 · Cited by 280
Sleep of professional athletes: Underexploited potential to improve health and performance
Tuomilehto, H., Vuorinen, V.-P., Penttilä, E., Kivimäki, M., Vuorenmaa, M., Venojärvi, M., Airaksinen, O., & Pihlajamäki, J. (2017) · Journal of Sports Sciences · doi:10.1080/02640414.2016.1184300 · Cited by 114
Eszopiclone: A Review of Its Use in the Treatment of Insomnia
Hair, P. I., McCormack, P. L., & Curran, M. P. (2008) · Drugs · doi:10.2165/00003495-200868100-00005 · Cited by 59
Hochverbrauch von Zolpidem und Zopiclon: Querschnittsstudie auf Basis von Krankenkassendaten
Hoffmann, F., Pfannkuche, M., & Glaeske, G. (2008) · Der Nervenarzt · doi:10.1007/s00115-007-2280-6 · Cited by 21
Metadata
- Authors
- Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., Bogg, J., Dickson, R., & Walley, T.
- Venue
- Health Technology Assessment
- Published
- 2004-06
- Volume
- 8
- Issue
- 24
- Pages
- iii-x, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2100397981
- Cited by
- 131
- References
- 15
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.